Brand Strategy
Name the two patients repeatedly referenced throughout the September meeting materials.
Andrea and Alan
Medicare Part D patients can access Zepbound through this program…
The Medicare Part D Bridge Program
This SURMOUNT study is commonly used to address the limiting belief that Andrea could succeed with diet and exercise alone.
SURMOUNT- 1
The new Simplified Access Slide (IVA) goes over what three ways to get Zepbound
Commercial
Medicare GLP1 Bridge
Self Pay
How do you address the following?
“PAP therapy alone is a more effective tool to manage OSA than Zepbound alone.”
Clarifying question? Go to slides? What does it sounds like?
Clarify: Prescribe comparing PAP’s efficacy directly to that of Zepbound alone? Thoughts on combining?
Slides:
SURMOUNT- OSA: AHI AND BODY WEIGHT REDUCTION
The acronym ACT stands for….
A- Address
C- Choose
T- Treat
This resource provides customers with an overview of Zepbound's affordability options by segment, device, and price. This resource was recently updated to include information on the Medicare GLP-1 Bridge, including what device can be prescribed and the expected out-of pocket cost for eligible patients.
Device Option Leave Behind
In this study, all the participants received a reduced- calorie diet and increased physical activity, making it useful when discussing the dditional benefit of Zepbound.
SURMOUNT- 1
This tool confirms whether Zepbound is available with or without insurance coverage.
EBV
How do you address the following?
“I don’t want to start patients on this medication because they will regain the weight as soon as they stop taking it.”
Clarifying question? Go to slides? What does it sounds like?
Clarify: How often do you see patients with obesity who experience weight regain with diet and exercise alone?
Slides:
SURMOUNT- 1 Weight Loss Over Time
SURMOUNT- 4 Weight Reduction Over Time
Out of 136 million US adults living with overweight or obesity- this percentage are treated with injectable incretin OMMs.
5%
This commercial plan will start covering Zepbound 10/1/2026, with some employers reinstating earlier, restoring access for ~25-30 million5 patients. When coverage stopped, ~400,0006 patients discontinued Zepbound and those patients are reachable again.
CVS
This study demonstrated superior body- weight reduction vs. Wegovy in a head to head trial.
SURMOUNT- 5
This sub study (from SURMOUNT 1) can now be found in the core flow of the Zepbound IVA.
SURMOUNT 1 BODY COMPOSITION
How do you address the following ….
”I think it’s the PCP’s responsibility to initiate treatment for a patient‘s obesity with Zepbound.”
Clarifying question? Go to slides? What does it sounds like?
Clarify: What hesitancies do you have to prescribe Z for your patients with moderate to severe OSA and obesity?
Slides:
Unmet Need… 24.1M adults are living with moderate to severe OSA and obesity. Only 1 in 5 are diagnosed.
SURMOUNT— OSA: AHI and Body Weight Reduction
Starting and Continuing Zepbound slide
According to the key takeaway, every call should end with this.
Commitment to start a specific appropriate patient today.
This tool provies you with a description of how Zepbound is covered across multiple payer segments to assist in your discussions with customers.
Open employer view to see which employers have access, ranked by OMM TRx volume for the OMM class, including 10/1, CVS upgrades. Use these tools to create print on demand sheets and VAEs, and to support live conversations with key office staff using the Formulary IVA
Access Genius
This study is used when an HCP believes patients will regain weight after stopping therapy.
SURMOUNT- 4
SURMOUNT 5 Head to Head v. Wegovy compares Zepbound 10mg & 15 mg to what doses of WEGOVY injection?
1.7mg & 2.4mg
How do you address the following?
“My patients can’t afford Zepbound”…
Clarifying question? Go to slides? What does it sounds like?
Clarify: Patient cost? In general? Indication persuing?
Slides:
Simplified access slide… Available w/ or w/o insurance. $25 for a 1 month prescription w/ coverage.
BRIDGE program $50 for those that qualify
Lilly Direct Pharmacy offers Zepbound for ALL patients $299- $449
What is Brands 2026 Bold Goal?
Help 5.4 million new patients living with overweight or obesity.
Name three out of the top ten CVS- opted in Employers in Mountain West territory.
State of Hawaii EUTF 130.2k
New Mexico Public Schools Ins. 49.3k
JPMorgan Chase 26.0k
U-Haul Amerco 23.3k
State Farm Insurance 19.9k
City of Seattle 17.0k
Bank of America 16.6k
Ross Stores 16.4k
AT&T 14.2k
CVS Health Employees 13.9k
This study provided evidence supporting Zepbound for moderate to severe OSA through reductions in AHI and body weight.
SURMOUNT OSA
The SURMOUNT-1 DXA substudy evaluated changes in these two components of body composition at 72 weeks.
Total body fat mass and body lean mass
How do you address the following?
”I prescribe Wegovy because it has a CV indication”…
Clarifying question? Go to slides? Why does it sounds like?
Clarify: Zepbound does not have CV outcome data or a CV indication.
Slides:
SURMOUNT-1 Weight Reduction >5%, >10%, 20%
Cardiometabolic Data Slide